208 related articles for article (PubMed ID: 21687736)
1. Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret.
Layton RC; Gigliotti A; Armijo P; Myers L; Knight J; Donart N; Pyles J; Vaughan S; Plourde J; Fomukong N; Harrod KS; Gao P; Koster F
PLoS One; 2011; 6(6):e20641. PubMed ID: 21687736
[TBL] [Abstract][Full Text] [Related]
2. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.
Layton RC; Petrovsky N; Gigliotti AP; Pollock Z; Knight J; Donart N; Pyles J; Harrod KS; Gao P; Koster F
Vaccine; 2011 Aug; 29(37):6242-51. PubMed ID: 21736913
[TBL] [Abstract][Full Text] [Related]
3. A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets.
Liu F; Sun X; Fairman J; Lewis DB; Katz JM; Levine M; Tumpey TM; Lu X
Virology; 2016 May; 492():197-203. PubMed ID: 26967975
[TBL] [Abstract][Full Text] [Related]
4. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
[TBL] [Abstract][Full Text] [Related]
7. A nanoemulsion-adjuvanted intranasal H5N1 influenza vaccine protects ferrets against homologous and heterologous H5N1 lethal challenge.
Smith D; Streatfield SJ; Acosta H; Ganesan S; Fattom A
Vaccine; 2019 Sep; 37(42):6162-6170. PubMed ID: 31495593
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.
Lin J; Zhang J; Dong X; Fang H; Chen J; Su N; Gao Q; Zhang Z; Liu Y; Wang Z; Yang M; Sun R; Li C; Lin S; Ji M; Liu Y; Wang X; Wood J; Feng Z; Wang Y; Yin W
Lancet; 2006 Sep; 368(9540):991-7. PubMed ID: 16980114
[TBL] [Abstract][Full Text] [Related]
9. Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial.
Howard LM; Hoek KL; Goll JB; Samir P; Galassie A; Allos TM; Niu X; Gordy LE; Creech CB; Prasad N; Jensen TL; Hill H; Levy SE; Joyce S; Link AJ; Edwards KM
PLoS One; 2017; 12(1):e0167488. PubMed ID: 28099485
[TBL] [Abstract][Full Text] [Related]
10. Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge.
Mann AJ; Noulin N; Catchpole A; Stittelaar KJ; de Waal L; Veldhuis Kroeze EJ; Hinchcliffe M; Smith A; Montomoli E; Piccirella S; Osterhaus AD; Knight A; Oxford JS; Lapini G; Cox R; Lambkin-Williams R
PLoS One; 2014; 9(5):e93761. PubMed ID: 24850536
[TBL] [Abstract][Full Text] [Related]
11. Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.
Lazarus R; Kelly S; Snape MD; Vandermeulen C; Voysey M; Hoppenbrouwers K; Hens A; Van Damme P; Pepin S; Leroux-Roels I; Leroux-Roels G; Pollard AJ
PLoS One; 2016; 11(11):e0165384. PubMed ID: 27814377
[TBL] [Abstract][Full Text] [Related]
12. Impact of Adjuvants on the Immunogenicity and Efficacy of Split-Virion H7N9 Vaccine in Ferrets.
Wong SS; Kaplan B; Zanin M; Debeauchamp J; Kercher L; Crumpton JC; Seiler P; Sun Y; Tang L; Krauss S; Webster R; Webby RJ
J Infect Dis; 2015 Aug; 212(4):542-51. PubMed ID: 25712975
[TBL] [Abstract][Full Text] [Related]
13. Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge.
Wang SH; Smith D; Cao Z; Chen J; Acosta H; Chichester JA; Yusibov V; Streatfield SJ; Fattom A; Baker JR
Vaccine; 2019 Mar; 37(12):1591-1600. PubMed ID: 30795941
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.
Bresson JL; Perronne C; Launay O; Gerdil C; Saville M; Wood J; Höschler K; Zambon MC
Lancet; 2006 May; 367(9523):1657-64. PubMed ID: 16714186
[TBL] [Abstract][Full Text] [Related]
15. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine.
Rockman S; Brown LE; Barr IG; Gilbertson B; Lowther S; Kachurin A; Kachurina O; Klippel J; Bodle J; Pearse M; Middleton D
J Virol; 2013 Mar; 87(6):3053-61. PubMed ID: 23283953
[TBL] [Abstract][Full Text] [Related]
16. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.
Baras B; Stittelaar KJ; Simon JH; Thoolen RJ; Mossman SP; Pistoor FH; van Amerongen G; Wettendorff MA; Hanon E; Osterhaus AD
PLoS One; 2008 Jan; 3(1):e1401. PubMed ID: 18167560
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.
Nicholson KG; Thompson CI; Klap JM; Wood JM; Batham S; Newman RW; Mischler R; Zambon MC; Stephenson I
Vaccine; 2009 Dec; 28(1):171-8. PubMed ID: 19799843
[TBL] [Abstract][Full Text] [Related]
18. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
[TBL] [Abstract][Full Text] [Related]
20. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
